Web Date: December 12, 2017
CRISPR gene editing is coming to the clinic
The gene editing technology CRISPR is one step closer to treating genetic diseases in humans. Last week, Crispr Therapeutics filed an application with European regulatory authorities to begin clinical trials for its CRISPR therapy CTX001 in a genetic blood condition called beta-thalassemia. The biotech firm expects to begin the trial—the first industry-sponsored study of a CRISPR drug—next year.
“It is a momentous occasion for both our company and the field,” says Samarth Kulkarni, CEO of . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society